title: Control of hepatitis B virus infection in dialysis units in Latium, Italy.
abstract: The prevalence of hepatitis B virus (HBV) markers was assessed in 1,841/2,178 (84.5%) dialysis patients (DP) cared for in 38/47 dialysis units (80.9%) in Latium. Among DP, 205 (11.1%) were HBsAg positive: 13.8% of males and 7.1% of females (p less than 0.001); the prevalence increased with the length of time on dialysis (p for trend less than 0.001). No differences in HBV (HBsAg and/or anti-HBc) distribution were seen related to age and sex. Of 664/1,539 vaccinated DP, 150 (22.6%) were anti-HBc positive and 239 (36.0%) positive for anti-HBs alone. Of 875/1,539 nonvaccinated patients, 146 (16.7%) had no HBV marker. Vaccination against HBV did not influence the diffusion of HBV in our dialysis units and must be coupled with the implementation of long-standing infection control strategies.
authors.affiliation: Department of Public Health, 2nd University, Rome, Italy.
authors.forename: E
authors.initials: E
authors.lastname: Franco
authors.forename: A
authors.initials: A
authors.lastname: Olivadese
authors.forename: M
authors.initials: M
authors.lastname: Valeri
authors.forename: F
authors.initials: F
authors.lastname: Albertoni
authors.forename: N
authors.initials: N
authors.lastname: Petrosillo
mesh_terms: D005260:Female; D006436:Hemodialysis Units, Hospital; D006509:Hepatitis B / Q000453:epidemiology / Q000517:prevention & control* / Q000635:transmission; D017325:Hepatitis B Vaccines; D006801:Humans; D017053:Infection Control; D007558:Italy / Q000453:epidemiology; D008297:Male; D006435:Renal Dialysis / Q000009:adverse effects; D014761:Viral Hepatitis Vaccines / Q000627:therapeutic use
chemical_list: D017325:Hepatitis B Vaccines; D014761:Viral Hepatitis Vaccines